Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

LaNova Medicines Announces the IND Approval of LM-101 by NMPA

  • 2022-11-15

  • Share:

Shanghai, November 15th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-101, an anti-SIRPα monoclonal antibody, has been approved by China NMPA.